Last reviewed · How we verify
Comparator: carvedilol
Comparator: carvedilol is a Beta-blocker with alpha-1 antagonist activity Small molecule drug developed by Organon and Co. It is currently FDA-approved for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.
At a glance
| Generic name | Comparator: carvedilol |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Beta-blocker with alpha-1 antagonist activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. This dual action decreases heart rate and contractility while causing vasodilation, making it effective for managing hypertension and heart failure by reducing cardiac oxygen demand and improving hemodynamics.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Left ventricular dysfunction following myocardial infarction
- Angina pectoris
Common side effects
- Dizziness
- Fatigue
- Bradycardia
- Hypotension
- Hyperglycemia
- Erectile dysfunction
- Bronchospasm
Key clinical trials
- DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis (PHASE4)
- Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival (NA)
- LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED) (PHASE4)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD " (PHASE2, PHASE3)
- The CLEVER Study - Coreg And Left Ventricular Mass Regression (PHASE3)
- Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD) (PHASE2)
- A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions (PHASE1)
- A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: carvedilol CI brief — competitive landscape report
- Comparator: carvedilol updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Comparator: carvedilol
What is Comparator: carvedilol?
How does Comparator: carvedilol work?
What is Comparator: carvedilol used for?
Who makes Comparator: carvedilol?
What drug class is Comparator: carvedilol in?
What development phase is Comparator: carvedilol in?
What are the side effects of Comparator: carvedilol?
What does Comparator: carvedilol target?
Related
- Drug class: All Beta-blocker with alpha-1 antagonist activity drugs
- Target: All drugs targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure with reduced ejection fraction
- Indication: Drugs for Left ventricular dysfunction following myocardial infarction
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing